VALGANCICLOVIR HYDROCHLORIDE (valganciclovir hydrochloride) by Hetero is [see microbiology ( )]. Approved for cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see )], cmv disease in kidney, heart and 3 more indications. First approved in 2022.
Drug data last refreshed 18h ago
[see Microbiology ( )].
Worked on VALGANCICLOVIR HYDROCHLORIDE at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition
Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition